As cannabis and cryptocurrencies have seen mainstream profile increases alongside one another,  both industries have earned their fair share of supporters and critics. One Wall Street expert, however, has his mind set on one.

Jason Karp, founder and portfolio manager of Tourbillon Capital Partners said on the Opportunities in Public and Private Markets podcast on May 8 that he believes investing in cannabis is a more important sector to take into consideration over cryptos.

“I think it is almost insane if you are an investor of any kind–public or private–to not have a strong opinion and not have basic knowledge on what’s going on with cannabis,” Karp said. “I would go so far as to say I think it’s far more important to be knowledgeable on this than it is to be on crypto.”

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Despite being initially against the drug, Karp experimented with it by attempting to treat his insomnia and did research based on a friend’s request. After that, he was converted to the industry.

“I realized that I was going to spend a lot more time on the research from an investment perspective of this because this is a $50 billion industry today, [where] only $6 to $8 billion is legal,” Karp said. “My belief is the dominos are falling now to progressively increase the legalization timeline.”

Karp’s firm describes itself as an alternative asset management firm, employing low net exposure and “fundamentally driven long/short equity strategy.”

The Wall Street expert didn’t detail on the podcast specific stocks or companies he recommends but did mention he would not invest in the Canadian billion dollar valuated cannabis companies.

Karp favors cannabis over crypto due to cash flow

In terms of cryptocurrencies, Karp explained he views the crypto business as employing the “greater fool theory,” meaning holding assets under the belief there will always be someone willing to pay a higher price for them.

“Betting on a cryptocurrency is betting that someone is going to pay you more for the same thing that you bought without any cash flow generation,” Karp said. “Whereas with [cannabis] if your cash flows grow, you could be wrong on whether people want to buy it from you or not but you still win.”

During the show, host Patrick O’Shaughnessy, CEO of O’Shaughnessy Asset Management, said whenever he meets with groups of investors in Canada, he gets more questions about the cannabis space than crypto–mostly due to the encouragement the industry has seen from the legalization process.

“That’s a foreign concept here in the US still, because of the legalization problem but what an interesting area of the market,” O’Shaughnessy said.

The Canadian federal government is set to legalize the drug for recreational consumption later this year after the actual bill obtains approval from the Senate. While the US is moving towards legalization with states individually voting on this decision,  despite the drug remaining illegal federally under the Controlled Substances Act (CSA). However, this year has seen an increase in decriminalization bills from US senators.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce its upcoming investor awareness initiatives. MustGrow continues to actively engage its key stakeholders – potential industry partners, shareholders and prospective investors – by increasing awareness of its remarkable natural mustard-derived crop protection products.

TODAY: The Future of Food Investment Conference – SnowCap Ventures
Tuesday, Nov. 24th at 1:50 pm ET
Investors Register Here

Keep reading... Show less